Neupro Patch, Extended Release
Product Images NDC 50474-802

Product Visual Gallery

This gallery contains 32 technical images submitted to the FDA as part of the official labeling for Neupro (NDC 50474-802). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Ucb, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Chemical Structure (Neupro 01)

FDA Label Image

Figure (Neupro 02)

FDA Label Image

Figure 1 (Neupro 03)

This text likely represents a graph or chart depicting the concentration of rotigotine (in ng/mL) over time (in hours) after administration on day 27 and day 30. The values for rotigotine concentration are given at 6, 12, 18, and 24 hours after administration. No further information is available.*

FDA Label Image

Figure A (Neupro 04)

FDA Label Image

Figure B (Neupro 05)

FDA Label Image

Figure C (Neupro 06)

FDA Label Image

Figure D (Neupro 07)

FDA Label Image

Figure E (Neupro 08)

FDA Label Image

Figure F (Neupro 09)

FDA Label Image

Figure G (Neupro 10)

FDA Label Image

Figure H (Neupro 11)

FDA Label Image

Figure I (Neupro 12)

FDA Label Image

Figure J (Neupro 13)

FDA Label Image

Figure K (Neupro 14)

FDA Label Image

Principal Display Panel (1 mg Pouch Carton)

FDA Label Image

Principal Display Panel (2 mg Pouch Carton)

FDA Label Image

Principal Display Panel (3 mg Pouch Carton)

FDA Label Image

Principal Display Panel (4 mg Pouch Carton)

FDA Label Image

Principal Display Panel (6 mg Pouch Carton)

FDA Label Image

Principal Display Panel (8 mg Pouch Carton)

FDA Label Image

Principal Display Panel (Kit Carton)

FDA Label Image

Neupro 22

FDA Label Image

Neupro 23

FDA Label Image

Neupro 24

FDA Label Image

Neupro 25

FDA Label Image

Neupro 26

Neupro is a transdermal system for rotigotine that is used to deliver 1mg/24 hours. It is manufactured by UCB, Inc. and has a registered trademark. The given text includes some packaging information and instructions as well, which might be difficult to interpret due to the erroneous scanning.*

FDA Label Image

Neupro 27

Neupro is a medication provided in the form of rotigotine transdermal system, used to treat Parkinson's disease and restless leg syndrome. It is available in a pack of 30 systems that have 2 mg/24 hours strength each. The medicine is manufactured by UCB, a pharmaceutical company located in Smyrna, Georgia. The text also includes some regulatory information and a trademark reference.*

FDA Label Image

Neupro 28

Neupro® is a transdermal system that contains rotigotine and is available in a strength of 3mg/24 hours. It is a registered trademark of UCB and is indicated for the treatment of Parkinson's disease. The text contains some illegible characters, which can affect the completeness and clarity of the information.*

FDA Label Image

Neupro 29

Neupro® (rotigotine transdermal system) is a registered trademark that comes in the form of a 4 mg/24 hours patch, NDC 50474-804.03, and is manufactured by UCB, Inc. It is a medication used to treat Parkinson's disease and restless legs syndrome. The other text contains some unclear characters and is not useful.*

FDA Label Image

Neupro 30

Neupro is a registered trademark of UCB Group of Companies. Neupro (rotigotine transdermal system) is available in 6 mg/24 hours. The package, containing 30 systems, is identified with NDC 50474-805.03. Detailed instructions for use and warnings can be found on the packaging.*

FDA Label Image

Neupro 31

Neupro® (rotigotine transdermal system) is a registered trademark of UCB, Inc. and is made in Germany. This document pertains to an 8mg/24 hours Neupro® product, which comes as a transdermal system. The text also includes some unrecognizable characters.*

FDA Label Image

Neupro 32

Neupro is a transdermal system used for the treatment of Parkinson's disease. It comes in two strengths, 2 mg/24 hours and 4 mg/24 hours. The package contains 17 systems that deliver 2 mg/24 hours each and 87 systems that deliver 4 mg/24 hours each. The transdermal system helps relieve symptoms such as uncontrollable sudden movements and muscle tremors commonly associated with Parkinson's disease. The product is associated with side effects such as vomiting, dizziness, sleepiness, etc. For complete information on dosage and application, consult the package instructions and full prescribing information. The product contains sodium metabisulfite and should be kept out of reach of children.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.